User:Mr. Ibrahem/Ipilimumab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Ipilimumab, sold under the brand name Yervoy, is a medication used to treat melanoma, renal cell cancer, mesothelioma, and non-small cell lung cancer (NSCLC).[6][7] It is often used together with nivolumab.[7] It is given by gradual injection into a vein.[7]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CTLA-4 |
Clinical data | |
Pronunciation | i pi lim′ ue mab |
Trade names | Yervoy |
Other names | BMS-734016,[1] MDX-010,[2] MDX-101 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611023 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous (IV) |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C6742H9972N1732O2004S40 |
Molar mass | 148634.46 g·mol−1 |
NY (what is this?) (verify) |
Common side effects include rash, itchiness, tiredness, diarrhea, nausea, fever, thyroid problems, shortness of breath, liver inflammation, and abdominal pain.[7] Other side effects may include intestinal inflammation, toxic epidermal necrolysis, and neuropathy.[6] It is a monoclonal antibody that attaches to and blocks CTLA-4 which increases T cell activity against cancer.[7]
Ipilimumab was approved for medical use in the United States and Europe in 2011.[7][6] In the United Kingdom it costs about £15,000 for 200 mg as of 2021.[8] In the United States this amount costs about 32,300 USD.[9]